• Neurocrine Biosciences average return on tangible equity for 2024 was 15.57, a 61.51% decline from 2023.
• Neurocrine Biosciences average return on tangible equity for 2023 was 9.64, a 86.46% increase from 2022.
• Neurocrine Biosciences average return on tangible equity for 2022 was 5.17, a 82.23% increase from 2021.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.